GSK agrees to acquire Nanjing MeiRui Pharma in China

GSK said 90% of the share capital of MeiRui is to be acquired from Pagoda Pharmaceuticals and the remaining 10% from Allergon in a move to further expand its presence in China, one of the fastest-growing emerging markets.

MeiRui is a Chinese pharmaceutical business with urology and allergy products portfolio, including Prostat for benign prostatic hyperplasia and Sheniting for overactive bladder syndrome.

GSK will gain access to this portfolio of products, as well as MeiRui’s established sales and marketing platform and a manufacturing facility in Nanjing City, Jiangsu Province, China.

Particularly, GSK, which sells Avodart as a treatment for benign prostatic hyperplasia (enlarged prostate), intends to leverage Nanjing MeiRui’s presence in the China urology business and build awareness for the product.